NGL Fine Chem Ltd

NGL Fine Chem Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

NGL Fine Chem Ltd

₹ 2,743 6.23%
05 Jun - close price
nglfinechem.com BSE: 524774 NSE: NGLFINE
About

Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health.[1]

Key Points

Business Overview:[1][2]
NGLFCL primarily manufactures veterinary pharmaceutical APIs and intermediates, catering to the antiprotozoal and anthelmintic therapeutic segments. Its products are used in the animal healthcare industry.

Product Profile:[3][4]
It has ~39 APIs (37 Veterinary APIs, 2 Human APIs), ~4 Intermediates, and ~12 finished dosage forms, etc., in the categories of Anthelmintics, Antiprotozoals, Ectoparasiticides, and Phosphorus Supplements

Website BSE NSE
  • Market Cap ₹ 1,695 Cr.
  • Current Price ₹ 2,743
  • High / Low ₹ 3,005 / 980
  • Stock P/E 40.7
  • Book Value ₹ 518
  • Dividend Yield 0.06 %
  • ROCE 15.1 %
  • ROE 13.9 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is expected to give good quarter

Cons

  • Stock is trading at 5.30 times its book value
  • Company has a low return on equity of 12.1% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
74 69 79 85 96 88 91 87 93 101 117 126 145
62 62 66 74 83 82 81 83 89 93 103 106 127
Operating Profit 12 8 13 11 13 6 11 4 4 8 14 20 18
OPM % 16% 11% 17% 13% 13% 7% 12% 4% 4% 8% 12% 16% 12%
1 4 4 4 4 6 5 0 -1 7 2 5 3
Interest 0 0 0 0 0 0 0 1 1 1 1 1 1
Depreciation 2 2 2 2 2 2 2 2 3 3 4 4 4
Profit before tax 11 9 15 13 14 10 13 1 -0 10 11 19 15
Tax % 23% 15% 24% 30% 24% 22% 25% 4% 44% 21% 26% 24% 24%
9 8 11 9 11 8 10 1 -1 8 8 15 11
EPS in Rs 13.81 12.64 17.76 14.41 17.56 12.67 16.25 1.26 -0.84 12.37 12.79 23.86 18.37
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
88 96 100 114 153 152 258 319 275 329 359 489
73 74 74 92 121 129 181 253 246 284 333 428
Operating Profit 15 22 25 22 32 23 77 66 29 45 27 60
OPM % 17% 23% 26% 19% 21% 15% 30% 21% 10% 14% 7% 12%
2 0 1 3 4 1 9 13 8 16 10 15
Interest 2 2 1 2 3 3 2 2 2 2 3 4
Depreciation 3 3 3 5 6 7 7 8 8 8 9 16
Profit before tax 13 18 23 18 28 14 76 69 27 51 24 55
Tax % 35% 36% 35% 29% 27% 26% 27% 24% 24% 24% 24% 24%
8 11 15 13 20 11 55 52 20 39 18 42
EPS in Rs 13.48 18.45 24.10 20.38 32.58 17.16 89.79 84.57 32.57 62.35 29.35 67.38
Dividend Payout % 0% 0% 0% 0% 5% 10% 2% 2% 5% 3% 6% 0%
Compounded Sales Growth
10 Years: 18%
5 Years: 14%
3 Years: 21%
TTM: 36%
Compounded Profit Growth
10 Years: 14%
5 Years: -6%
3 Years: 27%
TTM: 130%
Stock Price CAGR
10 Years: 27%
5 Years: 5%
3 Years: 21%
1 Year: 159%
Return on Equity
10 Years: 17%
5 Years: 14%
3 Years: 12%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 3 3 3 3 3 3 3 3 3 3 3 3
Reserves 30 41 56 69 89 98 152 203 222 260 277 317
13 14 23 27 27 28 16 30 32 34 76 108
21 19 20 31 23 26 34 41 30 56 70 102
Total Liabilities 67 78 102 129 142 156 206 278 288 353 426 530
17 24 25 56 61 61 58 59 59 60 120 144
CWIP 1 2 16 3 0 0 1 6 26 46 50 95
Investments 2 3 6 6 9 14 33 32 43 57 63 43
46 49 55 63 73 80 115 180 159 190 193 248
Total Assets 67 78 102 129 142 156 206 278 288 353 426 530

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
8 8 10 22 9 20 27 13 32 11 17 35
-3 -10 -10 -21 -10 -19 -24 -13 -24 -17 -16 -65
-4 2 0 0 0 -1 -1 -1 -1 -1 -1 30
Net Cash Flow 1 0 -0 1 -1 -0 2 -1 7 -7 0 0
Free Cash Flow 5 -2 -8 -1 -6 12 22 -2 3 -17 -56 -51
CFO/OP 80% 68% 70% 128% 50% 101% 61% 45% 134% 52% 86% 79%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 107 123 110 89 79 63 53 74 86 92 81 94
Inventory Days 106 90 114 134 106 154 132 133 69 99 95 102
Days Payable 150 122 139 187 92 114 94 84 59 110 105 90
Cash Conversion Cycle 63 91 85 35 93 103 91 124 97 82 71 106
Working Capital Days 38 49 45 18 70 63 71 89 67 71 51 88
ROCE % 29% 37% 34% 22% 28% 15% 52% 35% 12% 19% 8% 15%

Insights

In beta
Mar 2019 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Animal API Revenue Contribution
%

Log in to view insights

Please log in to see hidden values.

Login
Number of APIs (Commercial)
Count
R&D Expenditure as % of Turnover
%
Number of Customers
Count
Outsourced Production Share
%
Reactor Capacity
kl
Top 10 Products Revenue Contribution
%
Capacity Utilization
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
73.53% 73.06% 73.06% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.73%
0.00% 0.02% 0.04% 0.10% 0.03% 0.02% 0.05% 0.00% 0.00% 0.00% 0.00% 0.03%
0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
26.46% 26.93% 26.91% 27.16% 27.24% 27.25% 27.23% 27.26% 27.26% 27.26% 27.26% 27.23%
No. of Shareholders 17,06617,62316,41015,04114,60814,57514,11014,38614,01013,38712,83412,516

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls